Trials / Unknown
UnknownNCT01338103
Treatment of Pemphigus Patients With Rituximab 1000mgX2 and Assessment of Immune Status Via Cylex
Treatment of Moderate to Severe Patients With Pemphigus With the Monoclonal Anti CD20 Antibody Rituximab at a Protocol of 1000mgX2 and Assessment of Their Immune Status Via the Cylex Test
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- Rabin Medical Center · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine whether Rituximab, in the same doses as used in rheumatoid arthritis patients, will benefit pemphigus patients. It also tests immune function via the Cylex assay in pemphigus patients before and after treatment with RItuximab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Rituximab | intravenous (IV) Rituximab 1 gramX2, every (q) 2 weeks. |
Timeline
- Start date
- 2010-01-01
- Primary completion
- 2012-06-01
- Completion
- 2012-06-01
- First posted
- 2011-04-19
- Last updated
- 2011-05-02
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT01338103. Inclusion in this directory is not an endorsement.